04/23/2025 3:30 PM | Protalix BioTherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/17/2025 4:19 PM | Protalix BioTherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/17/2025 6:18 AM | Protalix BioTherapeutics (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
03/17/2025 5:55 AM | Protalix BioTherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/31/2024 3:30 PM | Protalix BioTherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/23/2024 6:01 AM | Protalix BioTherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/14/2024 6:03 AM | Protalix BioTherapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
11/14/2024 5:57 AM | Protalix BioTherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/05/2024 4:00 PM | Protalix BioTherapeutics (Issuer) Rubin Eyal (Reporting)
| Form 4/A | |
10/25/2024 3:23 PM | Protalix BioTherapeutics (Subject) WHITEBOX ADVISORS LLC (Filed by)
| Form SC 13G/A | |
10/25/2024 7:27 AM | Protalix BioTherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/24/2024 4:00 PM | Naos Yaron (Reporting) Protalix BioTherapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/24/2024 4:00 PM | Protalix BioTherapeutics (Issuer) Rubin Eyal (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/14/2024 6:02 AM | Protalix BioTherapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
08/14/2024 5:56 AM | Protalix BioTherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/10/2024 6:20 AM | Protalix BioTherapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/10/2024 5:59 AM | Protalix BioTherapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |